Loading...
Market
How will public opinion on NHS funding for Leqembi shift by August 22, 2025?
1
Resolution / Starting Odds
Significant increase in support • 25%
Moderate increase in support • 25%
No change in support • 25%
Decrease in support • 25%
Public opinion polls from reputable polling organizations
Story
UK Approves Costly Alzheimer's Drug Leqembi, Not Available on NHS
Aug 22, 2024, 09:19 AM
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqembi, also known as Lecanemab, a drug developed by Eisai and Biogen, which has been shown to slow the progression of Alzheimer's disease. Approved on Thursday, the drug is licensed for adult patients in the early stages of Alzheimer's. Despite its approval, Leqembi will not be available on the National Health Service (NHS) due to its high cost and limited benefits. The National Institute for Health and Care Excellence (NICE) has stated that the benefits of Lecanemab, which slows disease progression by an average of 4-6 months, do not justify the significant expense required for treatment and monitoring. This decision has sparked disappointment among patients and healthcare professionals, as the drug represents a significant advancement in Alzheimer's treatment.
View original story
Similar markets
More supportive • 25%
Less supportive • 25%
No significant change • 25%
Split opinion • 25%
Increased support • 33%
Decreased support • 33%
No significant change • 34%
More supportive of King Charles • 25%
More supportive of Prince Andrew • 25%
No significant change • 25%
Divided opinion • 25%
Majority Support • 25%
Majority Oppose • 25%
Evenly Split • 25%
No Clear Consensus • 25%
Significant improvement • 25%
Moderate improvement • 25%
No change • 25%
Decline • 25%
More support for Planned Parenthood funding • 25%
Less support for Planned Parenthood funding • 25%
No significant change in opinion • 25%
Mixed opinions • 25%
Privacy concerns • 25%
Access to services • 25%
Quality of care • 25%
Other • 25%
Support increases • 25%
Support decreases • 25%
Remains the same • 25%
No clear consensus • 25%
Supportive • 25%
Opposed • 25%
Indifferent • 25%
Unaware • 25%
Majority support • 25%
Majority oppose • 25%
Evenly split • 25%
Insufficient data • 25%
Increased support • 33%
Decreased support • 33%
No significant change • 34%
Significantly more negative • 25%
Slightly more negative • 25%
No significant change • 25%
More positive • 25%